# OnCo record pemigatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/pemigatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "pemigatinib" ;
  schema:name "Pemigatinib"@en ;
  schema:description "Pemigatinib was the first targeted therapy for bile duct cancer, for tumours with an FGFR2 gene fusion."@en ;
  schema:url <https://onco.cc/drugs/pemigatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Pemigatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q96398739> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pemigatinib>, <https://www.nice.org.uk/guidance/ta722> ;
  onco:status "approved" ;
  onco:modality "Small-molecule kinase inhibitor (FGFR1-3)" ;
  schema:alternateName "Pemazyre" ;
  onco:approval "US 2020: Previously treated FGFR2-fusion/rearranged cholangiocarcinoma (accelerated)", "EU 2021: Same", "UK 2021: Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after systemic therapy; NICE TA722 recommended 25 August 2021 with a commercial arrangement" ;
  onco:acceleratedApproval "US 2020-04-17: Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test." ;
  onco:related <https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/> ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:companies <https://onco.cc/companies/incyte/> ;
  onco:terms <https://onco.cc/terms/fgfr2-fusion/> ;
  onco:trials <https://onco.cc/trials/fight-202/> .